Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials
Summary
Envedas lead program for atopic dermatitis is a novel oral first-in-class anti-inflammatory agent that has demonstrated remarkable efficacy and high safety margins in preclinical studies. Close on its heels is another novel first-in-class anti-inflammatory that inhibits multiple cytokine signaling cascades in the gut to achieve robust efficacy in models of inflammatory bowel disease.At Premji Invest, we seek to partner with exceptional teams to build companies that can create long-term value. We are excited by Envedas potential to deliver new, safe and efficacious treatments for complex conditions, pushing the boundaries of AI and ML in life sciences, said Sandesh Patnam, Managing Partner at Premji Invest. We look forward to the new discoveries which can bring hope to millions of patients worldwide.Were proud to support Enveda as we see its potential for long-term, open-ended growth due to the broad utility of their technology for solving some of the toughest challenges facing human and planetary health, says Morgan Samet, Partner and Co-Head Lingotto Investment Management. Using their AI-powered tools to identify and characterize the wide range of molecules that are produced by living organisms the vast majority of which have never been explored by science Enveda is creating a new database of chemical biodiversity: the library of life.